Frontiers in immunology
TREM2+ macrophages mediate anticancer therapy-induced immune evasion in lung adenocarcinoma via the CCL5/CCL22-Treg axis
Par Kim CY, Cha YJ, Park MK et 1 autres.
Contenu en anglais
Résumé
Introduction
Osimertinib and cisplatin are widely used as standard treatments for non-small cell lung cancer (NSCLC); however, their effects on tumor microenvironment remodeling remain poorly understood. This study investigated whether TREM2-positive tumor-associated macrophages (TAMs) promote immune evasion through the CCL5/CCL22-CCR5/CCR4-Treg axis under anticancer treatment.
Methods
The spatial and quantitative correlations between TREM2+ and FOXP3+ cells were assessed using NSCLC patient-derived single-cell RNA sequencing (scRNA-seq) datasets, human lung adenocarcinoma tissue microarrays, and cisplatin-treated mouse lung cancer models. Mediators linking TREM2+ and FOXP3+ cells were identified by cell-cell communication analysis using CellChat and gene expression profiling of THP-1-derived macrophages treated with osimertinib or cisplatin, with validation in bone marrow-derived macrophages.